GERN: Geron approved for human stem cell trials

I traded GERN in the 90's, and it ran from 4 to 75 based on stem cell patents they were receiving (over 300 so far). They have FINALLY gotten approval, from the Obama admin, to inject stem cells into humans with spinal injuries. Their testing on lab mice showed incredible results, lets hope its the same for people. The approval for any drugs may get fast tracked, as victims of paralysis have no alternatives. Their research into aging came first, hence the company name, so they may have cures for Alzheimer's or cancer down the road. If so, the $50 target I've put here isn't even their old high, which was 75, and I can see the stock soaring to 100-200 before a takeover by a big pharma company, which GERN may actually fight. OF ALL the biotech I've followed for 25 yrs, this one has the most potential for HUMAN BREAKTHROUGHS that could usher in a new age of medicine. This is one you can buy, and put away and forget about awhile, but if it soars, take some profit and trade it. .. the Jman..